Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Deucravacitinib in Healthy Males
NCT03739788Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Primary endpoint: Absolute oral bioavailability (F) of BMS-986165 at 4 days. Started Dec 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03739788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739788.